Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

ACADIA Pharmaceuticals Inc

Healthcare US ACAD

22.6USD
0.51(2.31%)

Last update at 2026-06-23T20:00:00Z

Day Range

22.0122.66
LowHigh

52 Week Range

14.1828.35
LowHigh

Fundamentals

  • Previous Close 22.09
  • Market Cap3716.78M
  • Volume1476354
  • P/E Ratio9.48
  • Dividend Yield-%
  • EBITDA116.57M
  • Revenue TTM1071.51M
  • Revenue Per Share TTM6.37
  • Gross Profit TTM 653.71M
  • Diluted EPS TTM2.30

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 138.90M 258.07M -51.03600M -213.44400M -167.51900M
Minority interest - - - - -
Net income 391.00M 226.45M -61.28600M -215.97500M -167.87000M
Selling general administrative 548.89M 488.43M 393.07M 369.09M 396.03M
Selling and marketing expenses - - 9.40M - -
Gross profit 982.51M 875.96M 680.71M 507.07M 465.00M
Reconciled depreciation 11.76M 15.88M 5.55M 2.03M 3.34M
Ebit - 84.28M -73.37900M -225.62200M -173.78300M
Ebitda 138.90M 100.16M -67.82700M -223.59600M -170.43900M
Depreciation and amortization - 15.88M 5.55M 2.03M 3.34M
Non operating income net other - - - - -2.32900M
Operating income 104.81M 230.79M -73.37900M -223.59600M -170.43900M
Other operating expenses 966.69M 727.00M 799.82M 740.83M 654.58M
Interest expense - - - 6.61M 6.26M
Tax provision -252.09600M 31.62M 10.25M 2.53M 0.35M
Interest income 31.72M 25.46M 17.23M 6.61M 0.59M
Net interest income 31.72M 25.46M 17.23M 6.61M 0.59M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense -252.09600M 31.62M 10.25M 2.53M 0.35M
Total revenue 1071.51M 957.80M 726.44M 517.24M 484.14M
Total operating expenses 877.70M 645.16M 754.09M 730.66M 635.44M
Cost of revenue 89.00M 81.84M 45.73M 10.17M 19.14M
Total other income expense net 34.09M 27.28M 22.34M 10.15M 2.92M
Discontinued operations - - - - -
Net income from continuing ops 391.00M 226.45M -61.28600M -215.97500M -167.87000M
Net income applicable to common shares - - - -215.97500M -167.87000M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 1564.19M 1187.76M 748.96M 587.81M 700.12M
Intangible assets 108.89M 119.78M 65.49M - -
Earning assets - - - - -
Other current assets 59.53M 55.68M 39.09M 21.40M 23.89M
Total liab 336.81M 454.96M 317.20M 187.40M 159.23M
Total stockholder equity 1227.39M 732.79M 431.75M 400.41M 540.89M
Deferred long term liab - - - - -
Other current liab 254.88M 356.70M 225.74M 103.58M 80.89M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -1813.38600M -2204.38600M -2430.83700M -2369.55100M -2153.57600M
Other liab - - - 9.07M 7.03M
Good will - - 0.00000M - -
Other assets - - - 11.08M 15.98M
Cash 177.69M 319.59M 188.66M 114.85M 147.44M
Cash and equivalents - - - - -
Total current liabilities 277.11M 394.87M 254.25M 125.63M 96.07M
Current deferred revenue - - 1.56M - -
Net debt -125.50800M -267.59400M -131.45200M -52.84600M -91.30900M
Short term debt 11.63M 9.96M 9.40M 9.30M 8.30M
Short long term debt - - - - -
Short long term debt total 52.19M 51.99M 57.20M 62.00M 56.13M
Other stockholder equity 3039.32M 2936.87M 2862.55M 2770.92M 2694.65M
Property plant equipment - - - 61.59M 66.31M
Total current assets 1062.11M 938.32M 616.12M 507.94M 617.82M
Long term investments - - - - -
Net tangible assets - - - 400.41M 540.89M
Short term investments 641.99M 436.40M 250.21M 301.98M 373.27M
Net receivables 148.23M 104.69M 102.35M 63.08M 65.34M
Long term debt - - - - -
Inventory 34.67M 21.95M 35.82M 6.64M 7.88M
Accounts payable 10.90M 16.19M 17.54M 12.75M 6.88M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 1.45M 0.29M 0.02M -0.97500M -0.19200M
Additional paid in capital - - - - -
Common stock total equity - - - - 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -2153.57600M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 80.60M 78.87M 5.10M 18.28M 15.98M
Deferred long term asset charges - - - - -
Non current assets total 502.08M 249.44M 132.83M 79.88M 82.30M
Capital lease obligations 52.19M 51.99M 57.20M 62.00M 56.13M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments -199.03600M -30.53800M 32.00M 73.24M -69.98000M
Change to liabilities - - - 5.87M -8.21800M
Total cashflows from investing activities -302.56400M -30.53800M 32.00M 73.24M -71.10200M
Net borrowings - - - - -
Total cash from financing activities 49.88M 6.84M 25.13M 8.20M 18.16M
Change to operating activities - - - 27.54M -2.87800M
Net income 391.00M 226.45M -61.28600M -215.97500M -167.87000M
Change in cash -141.89400M 133.93M 73.81M -32.58900M -178.59300M
Begin period cash flow 319.59M 194.43M 114.85M 153.21M 331.80M
End period cash flow 177.69M 328.36M 188.66M 120.62M 153.21M
Total cash from operating activities 109.84M 157.72M 16.70M -114.03500M -125.66000M
Issuance of capital stock 49.88M 6.84M 25.13M 8.20M 18.16M
Depreciation 11.76M 15.88M 5.55M 2.03M 3.34M
Other cashflows from investing activities - 146.51M 32.05M - -
Dividends paid - - - - -
Change to inventory -18.19700M -49.55000M -28.80800M 2.42M -4.21000M
Change to account receivables -43.53600M -2.34500M -39.27000M 2.17M -16.11900M
Sale purchase of stock - - - - 18.16M
Other cashflows from financing activities - - 32.00M 73.24M -71.10200M
Change to netincome - - - 61.92M 61.29M
Capital expenditures 4.69M 0.52M 40.05M 0.00000M 1.12M
Change receivables - - - - -15.06200M
Cash flows other operating - - - - 2.67M
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -178.60000M
Change in working capital -89.75600M 4.16M 18.13M 37.99M -24.82400M
Stock based compensation 52.13M 67.05M 66.42M 68.20M 63.62M
Other non cash items 46.71M -155.81900M -12.11800M -6.27800M 0.07M
Free cash flow 105.15M 157.20M -23.34800M -114.03500M -126.78200M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
ACAD
ACADIA Pharmaceuticals Inc		 0.51 2.31% 22.60 9.48 50.76 3.47 3.07 2.80 25.72
NVO
Novo Nordisk A/S		 1.54 3.36% 47.42 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 - -% 45.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.63 0.35% 468.42 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 5.53 0.90% 618.03 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; ACP-711, which is in phase I clinical trial for the treatment of essential tremor; and ACP-271, a GPR88 agonist for the treatment of tardive dyskinesia and huntington's disease and is in phase I trial. In addition, the company develops ACP-2591, a cGP analogue which is in Phase 1 clinical trial to treat rett syndrome and fragile X syndrome; and STOKE Antisense Oligonucleotide Program, which is in discovery program for SYNGAP1 syndrome. It has a license agreement with Neuren Pharmaceuticals Limited to trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop, and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

ACADIA Pharmaceuticals Inc

12830 El Camino Real, San Diego, CA, United States, 92130

Key Executives

Name Title Year Born
Mr. Stephen R. Davis J.D. CEO & Director 1961
Dr. Srdjan R. Stankovic M.D., M.S.P.H. Pres 1957
Mr. Mark C. Schneyer Exec. VP & CFO 1974
Mr. Brendan P. Teehan Exec. VP, COO & Head of Commercial 1969
Mr. Austin D. Kim Exec. VP, Gen. Counsel & Sec. 1964
Mr. James K. Kihara VP, Chief Accounting Officer & Corp. Controller 1981
Mr. Bob Mischler Sr. VP of Strategy & Technology Operations NA
Mr. Mark C. Johnson VP of Investor Relations NA
Ms. Julie Fisher Sr. VP of Marketing & Commercial Strategy NA
Mr. Rob Ackles Sr. VP & Chief People Officer NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.